AvenCell is pioneering next-generation immunotherapies aimed at addressing the limitations of current T cell-based treatments for challenging cancers. Their proprietary platforms focus on allogeneic and switchable CAR-T cell technologies, which enhance the controllability of CAR-T reactivity while preserving high anti-tumor activity. This is achieved through a unique on/off mechanism that utilizes universal effector cells combined with soluble adaptors known as Targeting Modules (TMs). This innovative approach not only allows for precise targeting of cancer antigens but also significantly reduces the risk of acute and long-term side effects, such as cytokine release syndrome (CRS), thereby improving the safety profile and therapeutic window for patients.

AvenCell's pipeline includes several investigational therapies, such as AVC-101 and AVC-201, which are designed to treat acute myeloid leukemia (AML) using their Universal Targeting platform. These therapies leverage a regulatable CAR-T cell technology that can be turned on or off, addressing the challenges posed by on-target off-tumor toxicity. Additionally, AvenCell's allogeneic platform, developed in collaboration with Intellia Therapeutics, employs CRISPR/Cas9 technology to create T cell products that are more effective and have a lower risk of graft-versus-host disease (GvHD). This combination of advanced technologies positions AvenCell at the forefront of immunotherapy, with the potential to deliver safer and more effective treatments for patients with hematologic malignancies and solid tumors.

United States

AvenCell - Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.

AvenCell

Company Details